UVISERT

Serial Number 86593739
606

Registration Progress

Application Filed
Apr 10, 2015
Under Examination
Nov 3, 2015
Approved for Publication
Sep 8, 2015
Published for Opposition
Sep 8, 2015
Registered

Basic Information

Serial Number
86593739
Filing Date
April 10, 2015
Published for Opposition
September 8, 2015
Abandonment Date
December 10, 2018
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Dec 10, 2018
Classes
005 010

Rights Holder

EYEPOINT PHARMACEUTICALS US, INC.

03
Address
480 PLEASANT STREET, SUITE B300
WATERTOWN, MA 02472

Ownership History

pSivida US, Inc.

Original Applicant
03
Watertown, MA

pSivida US, Inc.

Owner at Publication
03
Watertown, MA

EYEPOINT PHARMACEUTICALS US, INC.

New Owner After Publication #1
03
WATERTOWN, MA

Legal Representation

Attorney
Jenevieve Maerker, Esq.

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

41 events
Date Code Type Description
Dec 10, 2018 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Dec 10, 2018 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
May 1, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 30, 2018 EX5G S SOU EXTENSION 5 GRANTED
Apr 25, 2018 EEXT I SOU TEAS EXTENSION RECEIVED
Apr 25, 2018 EXT5 S SOU EXTENSION 5 FILED
Apr 18, 2018 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Dec 7, 2017 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 7, 2017 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 3, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 1, 2017 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 1, 2017 EXT4 S SOU EXTENSION 4 FILED
Nov 1, 2017 EX4G S SOU EXTENSION 4 GRANTED
Apr 21, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 19, 2017 EEXT I SOU TEAS EXTENSION RECEIVED
Apr 19, 2017 EXT3 S SOU EXTENSION 3 FILED
Apr 19, 2017 EX3G S SOU EXTENSION 3 GRANTED
Nov 18, 2016 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 17, 2016 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 17, 2016 EX2G S SOU EXTENSION 2 GRANTED
Nov 2, 2016 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 2, 2016 EXT2 S SOU EXTENSION 2 FILED
Apr 16, 2016 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 14, 2016 EEXT I SOU TEAS EXTENSION RECEIVED
Apr 14, 2016 EXT1 S SOU EXTENSION 1 FILED
Apr 14, 2016 EX1G S SOU EXTENSION 1 GRANTED
Nov 3, 2015 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 8, 2015 PUBO A PUBLISHED FOR OPPOSITION
Sep 8, 2015 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 19, 2015 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 1, 2015 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 31, 2015 ALIE A ASSIGNED TO LIE
Jul 20, 2015 DOCK D ASSIGNED TO EXAMINER
Jul 20, 2015 DOCK D ASSIGNED TO EXAMINER
Jul 20, 2015 CNEA R EXAMINERS AMENDMENT -WRITTEN
Jul 20, 2015 GNEA F EXAMINERS AMENDMENT E-MAILED
Jul 20, 2015 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 20, 2015 XAEC I EXAMINER'S AMENDMENT ENTERED
Jul 20, 2015 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 20, 2015 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 14, 2015 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma
First Use Anywhere: 0
First Use in Commerce: 0
Class 010
Sustained drug delivery systems for ocular drugs
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 010